News and Announcements
MedAdvisor Signs Agreement with Novartis Pharmaceuticals to Deliver Patient Engagement & Education Program
- Published May 30, 2016 12:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th May 2016, ASX Announcement
Highlights:
- MedAdvisor signs a 12 month agreement with Novartis Pharmaceuticals Australia to deliver patient engagement and education program via the MedAdvisor platform
- Program will provide educational resources for patients, helping ensure they take their medications as prescribed to help improve patient adherence and quality use of medicines (QUMs)
- The program is to commence in June 2016 with three products initially and will run for 12 months
MedAdvisor Limited (ASX:MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a 12 month agreement to collaborate with Novartis Pharmaceuticals Australia.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
